866-997-4948(US-Canada Toll Free)

Global Cord Blood Banking Industry Report 2018

Published By :


Published Date : Apr 2018

Category :

In Vitro Diagnostics

No. of Pages : 267 Pages

After a rapid growth period through the mid-2000s, the global cord blood banking industry reached saturation and stabilized through approximately 2012. Since that time, the market has been aggressively consolidating. This has created both serious threats and novel opportunities for the industry.

Serious threats to the industry include low rates of utilization for stored cord blood, expensive cord blood transplantation procedures, difficulty educating obstetricians about cellular therapies, and an increasing trend toward industry consolidation.

There are also emerging opportunities for the industry, such as accelerated regulatory pathways for cell therapies in leading healthcare markets worldwide, including the United States, Japan, Europe and South Korea.

Cord Blood Industry Trends

New themes are impacting the industry, including the pairing of stem cell storage services with genetic and genomic testing services, as well as reproductive health services. Cord blood banks are diversifying into new types of stem cell storage, including umbilical cord tissue storage, placental blood and tissue, amniotic fluid and tissue, and dental pulp.

Cord blood banks are also investigating means of becoming integrated therapeutic companies, with LifebankUSA becoming an asset of the augmented immunity and longevity company Celularity and Americord announcing in a press release that it “intends to launch its first therapeutic product offering sometime in 2018.”

With approximately 450 companies offering cord blood banking services worldwide, maturation of the market means that each company is fighting harder for market share.

Cord Blood Industry Consolidation

Growing numbers of investors are now entering the marketplace, with M&A activity accelerating in the U.S. and abroad. In the United States, AMAG Pharmaceuticals sold Cord Blood Registry (CBR) to GI partners for $530 million in June 2018. AMAG had previously bought CBR for $700 million in 2015. GI Partners, a private equity investment firm, simultaneously acquired CBR and California Cryobank (CCB) to merge the companies into a single entity that will be the global leader in stem cell storage and reproductive tissue services.

Holding companies are also emerging as a global theme, allowing for increased operational efficiency and economy of scale. Cryoholdco has established itself as the market leader within Latin America. Created in 2015, Cryoholdco is a holding company that will control nearly 200,000 stem cell units by the end of 2018. It now owns six cord blood banks, as well as a dental stem cell storage company.

Globally, networks of cord blood banks are also commonplace, with Sanpower Group establishing dominance in Asia. Although Sanpower has been quiet about its operations, its website states:

“In 2016, Sanpower Group and its subsidiary Nanjing Cenbest announced their participation in founding a foundation to buy CO. In the same year, Nanjing Cenbest also acquired Shandong Cord Blood Bank. As a result, Sanpower now holds 4 licenses out of only 7 issued provincial-level cord blood bank licenses in China. It has reserved over 900,000 cord blood samples at home, and the associated reserves amount to almost 1,200,000 when counting in the Cordlife reserves across Southeast Asian countries and regions.”

This positions Sanpower Group and its subsidiary Nanjing Cenbest as the world’s largest cord blood banking operator not only in China and Southeast Asia, but in the world.

The number of cord blood banks in Europe has dropped by approximately one-third over the past ten years, from approximately 150 to 100. The industry leaders in this market segment include FamiCord Group, who has executed a dozen M&A transactions, and Vita34, who has executed approximately a half dozen. Stemlab, the largest cord blood bank in Portugal, also executed three acquisition deals prior to being acquired by FamiCord in July 2018.

FamiCord is now the leading stem cell bank in Europe, controlling over 263,000 cord blood and tissue units among its network of banks and over 347,000 biological samples of all types. This places it among the leading cord blood banks worldwide.

Dozens of other cord blood industry acquisitions have also occurred worldwide, with the highest frequency occurring within the United States, Europe, and Latin America.

Digital Competition for Cord Blood Banking Services

Digital competition for cord blood has been growing increasingly competitive. The term “cord blood” has now become one of the 20 most expensive search terms on Google. Winning online traffic through Google AdWords for the search phrase “Cord Blood” now costs $45.87 in the United States.

The cost for acquiring traffic through Google AdWords for the phrase “Cord Blood” is $32.91 when all geographies are allowed.

Cord Blood Expansion Technologies

Because cord blood utilization is largely limited to use in pediatric patients, growing investment is flowing into ex vivo cord blood expansion technologies.

Key strategies being explored for this purpose include:

  • Nicotinamide-mediated (NAM) expansion
  • Notch ligand
  • SR-1
  • UM171
  • PGE2
  • Enforced fucosylation

Currently, the following companies have ex vivo cord blood expansion products in Phase II clinical trials: 

Gamida Cell Ltd
Nohla Therapeutics
Magenta Therapeutics has a Phase I trial underway for its cord blood expansion technology.

Growing numbers of investors are also entering the cord blood banking marketplace, led by groups such as GI Partners, ABS Capital Partners & HLM Management, KKR & Company, Bay City Capital, GTCR, LLC, Excalibur, and more.

Global Cord Blood Banking Industry Dynamics

In 2008, a Taiwanese company, HealthBanks Biotech Company Ltd. became the first company to offer cord tissue storage. It was not until July 2010 that the first private U.S. cord blood bank began offering the service (Cord Blood Registry). Since then, the trend of cord tissue storage has had a major impact on the cord blood banking industry, with many cord blood banks worldwide now offering the service.

In China, the government shocked the industry by announcing that only one cord blood bank would be allowed to operate within each province, and official government support, authorization, and permits would be required.

In Italy and France, it is illegal to privately store one’s cord blood, which has fully eliminated the potential for a private market to exist within the region.

In Ecuador, the government is now creating the first public cord blood bank and has instituted laws such that private cord blood banks cannot approach women about private cord blood banking options during the first six months of pregnancy. This created a crisis for the private banks, and there are now only two remaining in Ecuador.

Most recently, India’s Central Drugs Standard Control Organization (CDSCO) restricted commercial banking of stem cells from most biological materials, including cord tissue, placenta, and dental pulp stem cells, leaving only umbilical cord blood banking as “permitted and licensed” within the country.

While market factors can vary by geography, it is crucial to have a global understanding of the market. Research advances, clinical trial findings, and technology advances do not know 

international boundaries.The cord blood market is global in nature and understanding dynamics limited to your region is not sufficient for making strategic, informed, and profitable decisions.

Cord Blood Report Highlights

This 265 page reports includes:

  • Market size determinations for cord blood and tissue storage, with projections to 2022
  • Volumes of cord blood and cord tissue storage worldwide
  • Rates of worldwide cord blood storage (units per year)
  • Rates of cord blood utilization
  • Trend rate data for umbilical cord blood grants, patents, and scientific publications
  • Clinical trial analysis, including comparison of cord blood vs. cord tissue trials
  • Current and future conditions treatable with cord blood
  • Regulatory pathways affecting cord blood banking in major healthcare markets
  • Digital marketing assessment and comparison of industry leaders
  • Competitive environment analysis, including identification of market leaders
  • Leading investors within the cord blood marketplace
  • Medical opinions on cord blood banking
  • Crucial trends and unmet market needs

Companies Mentioned

  • ABS Capital Partners & HLM Management
  • AllCells
  • AMAG Pharmaceuticals
  • AlphaCord
  • Americord
  • Bay City Capital
  • BioEden
  • Biocell Center
  • Biosafe
  • CariCord
  • Cell Care (Australia)
  • Cesca Therapeutics
  • China Cord Blood Corporation (CCBC)
  • CorCell
  • Cord Blood Registry (CBR)
  • Cordlife
  • Core23 BioBank
  • Crioestaminal
  • Cryo-Cell International
  • Cryoholdco
  • Cryolife
  • CryoSave
  • Dentcell
  • Excalibur
  • FamilyCord
  • Fate Therapeutics
  • Future Health Biobank
  • Gamida Cell Ltd.
  • GeneCell International
  • Genesis Bank
  • GI Parnters
  • HealthBaby
  • HealthBanks Biotech Company Ltd
  • Human Longevity Inc.
  • Insception Lifebank
  • KKR & Company
  • LifebankUSA
  • LifeCell International
  • Lonza
  • MAZE
  • MiracleCord
  • Nanjing Cenbest
  • Natera, Inc. (EverCordTM)
  • New England Cord Blood Bank
  • National Cord Blood Program (NCBP) at the New York Blood Center
  • Nohla Therapeutics
  • Novartis
  • PacifiCord
  • PerkinElmer
  • Pluristem Therapeutics
  • Precious Cells Group (now in administration, along with Pharmacells Ltd.)
  • PromoCells
  • ReeLabs
  • Sanpower Group
  • Shandong Cord Blood Bank
  • Stem Cell Cryobank
  • STEMCELL Technologies
  • StemCyte
  • Thermo Fisher Scientific
  • Transcell Biologics Pvt Ltd,
  • VAULT SC Inc.
  • ViaCord
  • Vita34 AG
  • And More

Table of Content

Global Market Requires Global Understanding
Cord Blood Stem Cells, Compared to Other Stem Cell Alternatives
Awareness Levels as a Factor Impacting Market Penetration
Digital Competition for Cord Blood
Key Report Findings
Timeline of Key Events
Table Timeline of Key Events within the Cord Blood Industry
Technical & Medical Characteristics of Cord Blood
Introduction to Cord Blood and Cord Tissue
Definitions and Nomenclature
Technical Advantages of Cord Blood
Likelihood of Needing a Stem Cell Transplant
Table Childhood Probability of Requiring a Stem Cell Transplant
Table Adulthood Probability of Requiring a Stem Cell Transplant
Comparison of Cord Blood, Bone Marrow, & Peripheral Blood Stem Cell Transplant
Conditions Treatable with Cord Blood Transplant
Table Disease Categories Treatable with Hematopoietic Stem Cell Transplantation (HSCT)
Table Disease Categories That May Be Treatable with HSCT in the Future
Cord Blood Market Overview
Stem Cell Storage Service Offerings
Public vs. Private Cord Blood Storage
Table Free Cord Blood Programs for Families in Need in the U.S.
Cord Tissue Market Overview
History of Cord Tissue Storage
Comparison of Cord Blood & Cord Tissue Storage
Clinical Trials Investigating Cord Tissue Derived Mesenchymal Stem Cells (CT-MSCs)
Table Clinical Trials Investigating the Use of Cord Tissue Derived Mesenchymal Stem Cells (CT-MSCs)
Table Clinical Trials Underway Involving Use of Wharton's Jelly, a Rich Source of Cord Tissue MSCs
Sources of Mesenchymal Stem Cells
Table Adult Sources for Mesenchymal Stem Cell (MSC) Isolation
Table Fetal Sources for Mesenchymal Stem Cell (MSC) Isolation
Market Penetration of Cord Tissue Storage within the U.S.
Table U.S. Cord Blood Banks Offering Cord Tissue Storage in 2013
Table U.S. Cord Blood Banks Offering Cord Tissue Storage in 2015
Market Penetration of Cord Tissue Storage Worldwide
Table Percent of Cord Blood Banks Worldwide Offering Cord Tissue Storage Services
Pricing of Cord Tissue Storage (Global Analysis)
Table Pricing Structures for Umbilical Cord Tissue
Benefits of Mesenchymal Stem Cells
Key Dates in the Discovery of MSCs
Physical Assessment of MSCs
Benefits of MSCs Relative to Other Stem Cells
Diverse Differentiation Potential
Ease of Growth in Culture
Flexible Propagation
Clinically Relevant Volumes
Role as Regulatory Cells
Delivery of Gene Products
Favorable Immune Status
Commercially Available Research Tools
Cord Blood Industry Accreditations
Overview of Cord Blood Industry Accreditation
AABB Accreditation
Table Countries Containing AABB Accredited Cord Blood Banks
Key Processing Technologies within the Cord Blood Marketplace
AutoXpress(R) Platform ("AXP(R)") and BioArchive System (By Thermogenesis, a Division of Cesca Therapeutics in Rancho Cordova, California, USA)
Sepax (By Biosafe, in Eysins, Switzerland)
PrepaCyte(R)-CB (By BioE in St. Paul, Minnesota, USA) - Cryo-Cell Purchased Rights to it in 2015
Cord Blood 2.0TM (By Americord, in New York, NY, USA)
Other Cord Blood Processing Technologies
Strategic Collaborations: Key Alliances within the Cord Blood Industry
Cord Blood Registry and Women's Health Alliance (Largest Women's Healthcare Groups)
ViaCord and Destination Maternity (Largest Retailer of Maternity Clothing)
Precious Cells Miracle and the Croydon Health Services NHS Trust
CarePilot and "Cord for Life" (Lifeforce Cryobank's Cord Blood Storage Program)
Cesca Therapeutics and UpState Public Cord Blood Bank
New York Blood Center and Pluristem Therapeutics Collaborate on Adjuvant Therapy for Cord Blood Transplantation
Pairing Cord Blood Banking with Prenatal / Neonatal / Maternal Health Services
Natera, a leader in genetic testing, launches EverCord™ Cord Blood and Tissue Banking Services (March 2017)
ViaCord, owned by parent company PerkinElmer, launched Newborn Genetic Screening (August 2017)
Human Longevity Inc. acquired LifeBankUSA (owned by Celgene); LifeBankUSA Now Passed to Celularity, Inc.
AMAG Pharmaceuticals acquired Cord Blood Registry to bolster its portfolio of maternal health products (June 2015)
Donor Egg Bank offers free processing of its clients' newborn cord blood through its sister company, FamilyCord
Cord Blood Industry Consolidation (Mergers and Acquisitions)
Global Analysis of Mergers & Acquisitions
Role of Holding Companies within the Global Cord Blood Industry
Technologies for Cord Blood Stem Cell Expansion
Key Strategies for Cord Blood Expansion
Case Study: Gamida Cell as an Industry Leader in Cord Blood Expansion Technology
Diversification of Stem Cell Storage Services
Table Types of Stem Cell Banking
Dental Stem Cell Storage
Table Companies Offering Dental Stem Cell Storage, Including Cord Blood Banks and Specialty Companies
Adipose-Derived Stem Cell Storage
Table Companies Offering Adipose-Derived Stem Cell Storage (Both Cord Blood Banks and Specialty Companies)
Other Types of Stem Cell Storage
Comparison of U.S. Cord Blood Market Leaders
Cord Blood Registry
Cryo-Cell International
Comparison of Top 3 Private U.S. Cord Blood Banks
Table Unique Differentiators for CBR, ViaCord, and Cryo-Cell
Table Comparison of Services and Features Among Leading U.S. Private Cord Blood Banks
Table Comparative Analysis of Pricing Among Leading U.S. Private Cord Blood Banks
Comparison of Global Cord Blood Market Leaders
Cryo-Save Group (an Esperite N.V Company)
Table Esperite N.V. Subsidiaries Operating Worldwide198
China Cord Blood Corporation (Owned by Sanpower Group)
LifeCell International
Comparison of International Cord Blood Banks
Table Comparison of Services and Features Among Leading Private Cord Blood Banks Worldwide
SWOT Analysis for Cord Blood Industry
Regulation of the Cord Blood Marketplace
Regulation of HCT/Ps by the U.S. FDA
21st Century Cures Act and REGROW Act
Accelerated Approval Pathways for Cell Therapies in Japan
Accelerated Approval Regulator Pathways Worldwide
Trend Rate Analysis
Scientific Publication Rate Analysis
Table Trend Rate Analysis of Cord Blood and Cord Tissue Scientific Publications
Grant Funding Analysis
Table Trend Rate Analysis of Cord Blood Grants (RePORTER Tool)
Patent Analysis
Table Patents Containing "Cord Blood" in the Title or Abstract (Google Patent Search)
Table Breakdown of Cord Blood Patents by Country
Table Cord Blood Banks Securing Cord Blood Patents as the Assignee
Clinical Trial Analysis
Table Cord Blood Clinical Trials Registered at ClinicalTrials.gov
Table Geographic Breakdown of "Cord Blood" Clinical Trials Registered at ClinicalTrials.gov
Market Penetration Rate of Cord Blood Storage
Cord Blood Online Marketing Analysis
Cost to Win Online Traffic for the Term "Cord Blood" in Google AdWords
Cost to Win Online Traffic for the Term "Cord Tissue" in Google AdWords
Table Google AdWords Pay-Per-Click Prices for Cord Blood Related Search Terms
Key Cord Blood Industry Benchmarks
Medical Society Opinions of Cord Blood Banking
Table Cord Blood Banking Opinions Issued by Medical Societies
Rates of Parental Awareness
Rates of Worldwide Storage, by Year
Table Cord Blood Units in the Bone Marrow Donors Worldwide Database
Transplant Data
Table Transplants by Cell Source (Donor registry of the C.W. Bill Young Cell Transplantation Program, including the National Cord Blood Inventory) 262
Impact of Haploidentical Transplant
Quality Guarantee Comparison
Table Comparison of Quality Guarantees Among Private U.S. Cord Blood Banks (Ranked by Value of the Guarantee)
Market Size Analysis
Roll-up all competitor sales ("Gold Standard")
Use a weighted analysis of industry leaders ("Silver Standard")
Survey customers for how much they spend in the market ("Bronze Standard")
Types of Market Participants
Largest Market Participants
Table Number of Cord Blood and Tissue Units Stored in Largest Private Cord Blood Banks
Mid-Sized Market Participants
Table Number of Cord Blood and Tissue Units Stored by Mid-Sized Private Cord Blood Banks
Small Sized Market Participants
Public Cord Blood Banking Sector
Table Percent of Total Global Market by Type of Cord Blood Bank
Summary of Findings
Table Breakdown of Global Market by Type of Participant
Market Size Determination for Cord Blood and Tissue Banking Market
Table Trends in Cord Blood Industry Growth by Geography and Sector
Table Global Cord Blood and Tissue Banking Market, by Type of Market Participant
Table Market Contribution in USD ($) by Type of Market Participant
Market Segmentation for All Applications of Cord Blood and Cord Tissue
Use in Hematopoietic Stem Cell Transplantation (HSCT)
Cellular Therapies
Genetic Manipulation
Research Tools
Table Comparison of Stem Cell Publication Rates by Stem Cell Type
Market Size Determinations by Market Segment
Table Market Size Determinations by Market Segment
Table Market Contribution in USD ($) by Market Segment
Cord Blood Industry Leadership
Cord Blood Industry Authorities
Top Ten Most Influential Cord Blood Banks Worldwide
Global Cord Blood Conferences and Events
Table Global Cord Blood Conference and Events
Investors and Acquisitions Impacting the Global Cord Blood Industry
Table Industry Investors within the Cord Blood Market
Table Major Acquisitions within the Global Cord Blood Market
Investors Impacting the Global Cord Blood Market
Three Strange Similarities between Acquisition of Cord Blood Registry & ViaCord
Table Comparison of Acquisition of Cord Blood Registry by AMAG Pharmaceuticals and ViaCord by PerkinElmer
Geographic Analysis of Evolving Cord Blood Industry Conditions
France and Italy
South Africa
Summary of Conclusions
Conditions Treatable with Hematopoietic Stem Cell Transplant (Including Cord Blood Transplant)
AABB Accredited Cord Blood Banks Worldwide307
List of U.S. Cord Blood Banks by Type of Bank (Private, Hybrid, or Public)
Global List of Cord Blood Banks Worldwide

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *